| Chiesi Licenses Bioasis Tech to Tackle Brain Symptoms of Rare Diseases | Sarah de Crescenzo | 07/01/20 | Boston |
| Viela Bio Gets FDA Green Light for Rare Autoimmune Disease Treatment | Sarah de Crescenzo | 06/12/20 | National |
| Reata Bags $350M as It Preps Rare Chronic Kidney Disease Drug for FDA | Sarah de Crescenzo | 06/11/20 | Texas |
| PTC Therapeutics to Acquire Censa Pharma for Mid-Stage Rare Disease Drug | Sarah de Crescenzo | 05/07/20 | New York |
| RDMD Lands $14M to Expand Reach of Rare Disease Research Platform | Sarah de Crescenzo | 04/16/20 | San Francisco |
| Blackstone Pays Alnylam $1B to Grab a Stake in RNAi Drug Inclisiran | Frank Vinluan | 04/13/20 | Boston |
| Rubius Drops Rare Diseases, Turns to Cancer and Autoimmune Disorders | Sarah de Crescenzo | 03/12/20 | Boston |
| Insmed Drug for Rare Pulmonary Disorder Meets Phase 2 Goals | Sarah de Crescenzo | 02/03/20 | New York |
| Perceptive Unveils New $210M Fund to Invest in Early-Stage Biotechs | Frank Vinluan | 12/10/19 | New York |
| Astellas Bets On Gene Therapy With $3B Audentes Acquisition Offer | Sarah de Crescenzo | 12/03/19 | National |
| Emtora Biosciences Turns Sights on Rare Genetic Disease, New Funding | David Holley | 04/30/19 | Texas |
| Rare-Disease Hackathon Leads to $3M for Health Data Startup RDMD | Alex Lash | 08/20/18 | San Francisco |
| EU Regulators Approve Akcea’s Inotersen. FDA Decisions Are Next. | Alex Lash | 07/11/18 | Boston |
| Bio Roundup: Hope for Lungs, Bradner’s Complaint, FDA Nods & More | Alex Lash | 04/20/18 | National |
| Bio Roundup: Trump Health, Cholesterol Wars, 23andMe OK & More | Alex Lash | 03/09/18 | National |
| Bio Roundup: Nobel Pursuit, Fundraising Fruit, A Rhythmic IPO & More | Alex Lash | 10/06/17 | National |
| Amicus’s Scioderm Deal Flops as Skin Drug Fails in Phase 3 | Ben Fidler | 09/13/17 | New York |
| Bio Roundup: Senate Drama, A.I. Stories, Data Dives, Shkreli & More | Alex Lash | 06/30/17 | National |
| Synlogic and Its Modified Bacteria Take Over Dying Company, Go Public | Alex Lash | 05/16/17 | Boston |
| FDA Approves BioMarin Drug, A First for Rare Genetic Batten Disease | Frank Vinluan | 04/27/17 | San Francisco |
| Ionis Pharma Spins Out Lipid Disorder Unit Akcea with Plans for IPO | Frank Vinluan | 03/27/17 | Boston |
| Often Advocates Of Faster FDA, Patient Groups Wary Of Trump Deregulation | Alex Lash | 02/10/17 | National |
| Notes From The JPM ’17 Vortex: Trump, Rainstorms & The Price You Pay | Alex Lash | 01/13/17 | National |
| Amicus Takes Aim at Rare Brain Disorder with MiaMed Acquisition | Frank Vinluan | 07/06/16 | New York |
| Inhaled-Drug Maker Savara Buys European Biotech With Two Candidates | David Holley | 06/21/16 | Texas |
| Ra Pharma Gets $58.5M in Crossover Cash to Target Rare Blood Disease | David Holley | 07/23/15 | Boston |
| Horizon Pays $1.1 Billion for Hyperion’s Rare Disease Drugs | David Holley | 03/30/15 | San Francisco |
| With $2M Seed, Perlstein Lab Tests Unorthodox Rare-Disease Plan | Alex Lash | 07/31/14 | San Francisco |
| West Coast Biotech Roundup: Genentech, CareDx, and More | Alex Lash | 07/17/14 | San Diego |
| With $22M, True North Points Toward Rare-Disease Clinical Trials | Alex Lash | 06/17/14 | San Francisco |
